Categories Earnings, Technology

Accenture (ACN) beats Q2 revenue and earnings estimates

Accenture expects revenues to be $10.75 billion to $11.15 billion for the third quarter of 2020

Accenture (NYSE: ACN) reported revenue and earnings that surpassed market expectations for the second quarter of 2020. The stock was up by 3.2% in premarket hours on Thursday.

Revenues increased 7% to $11.14 billion versus the prior-year period. Revenues grew 8% in local currency. The topline results were ahead of forecasts of $11.11 billion.

Accenture beat Q2 2020 revenue and earnings estimates

Net income attributable to Accenture was $1.23 billion, or $1.91 per share, compared to $1.12 billion, or $1.73 per share, in the prior-year period. Analysts had forecast EPS of $1.72.

New bookings were $14.2 billion, with consulting bookings of $7.2 billion and outsourcing bookings of $7 billion. Consulting revenues increased 7% while outsourcing revenues grew 6% in the quarter.

Days services outstanding, or DSOs, were 39 days at Feb. 29, 2020, compared with 40 days in the same period a year ago.

The company saw revenue increases across all its operating groups and geographic regions during the quarter, with the exception of Europe which remained flat compared to the year-ago period.  

Accenture declared a quarterly cash dividend of $0.80 per share, payable on May 15, 2020, to shareholders of record on April 16, 2020.

For the third quarter of 2020, Accenture expects revenues to be $10.75 billion to $11.15 billion, reflecting a growth of negative 2% to positive 2% in local currency.

The company has lowered its guidance for fiscal year 2020 to reflect the impact of the coronavirus epidemic. Revenue growth is now expected to be in the range of 3-6% in local currency, compared to the previous range of 6-8%. Diluted EPS is now estimated to be $7.48 to $7.70, versus the prior guidance of $7.66 to $7.84.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top